Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

377.55USD
4:00pm EDT
Change (% chg)

$-6.61 (-1.72%)
Prev Close
$384.16
Open
$384.16
Day's High
$385.78
Day's Low
$374.40
Volume
169,215
Avg. Vol
280,243
52-wk High
$453.40
52-wk Low
$281.89

Select another date:

Mon, Oct 1 2018

SCOTUS denies Regeneron request for review of inequitable conduct finding

Regeneron Pharmaceuticals Inc on Monday hit a dead end in its long-running bid to undo a ruling that a patent it had sought to enforce against rival Merus NV was unenforceable because it had been obtained through deception.

Sanofi, Regeneron skin cancer drug gets FDA nod

Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

UPDATE 1-Sanofi, Regeneron skin cancer drug gets FDA nod

Sept 28 Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Sanofi, Regeneron skin cancer drug gets FDA nod

Sept 28 Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.

Regeneron's anti-blindness drug approved for less frequent treatments

Aug 17 Regeneron said on Friday it had won U.S. Food and Drug Administration approval for less-frequent applications of its Eylea anti-blindness treatment, which may come under pressure from a rival product made by Novatis

Regeneron to invest $100 million in bluebird, jointly develop cancer therapies

Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer.

Regeneron posts quarterly profit beat, strongly backs Eylea's future

Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday, helped by higher sales of its newer medicines and outlined a growth strategy for its flagship drug Eylea, which is facing heightened competition.

Regeneron profit beats expectations on sales of eczema drug

Aug 2 Drugmaker Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit, helped by higher sales of eczema drug Dupixent.

Regeneron's newer drugs disappoint, shares slip

Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company's future sales growth as its best-selling eye drug Eylea faces more competition.

UPDATE 3-Regeneron's newer drugs disappoint, shares slip

* Shares down 2 pct (Adds background, comments from conf. call and analyst, updates shares)

Select another date: